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Purpose/Objective: The purpose of this study was to verify safety 
interlocks consistent with international standards IEC 60601-2-1 using 
a linear accelerator Coline 6 control system developed through the 
European Accelerators & Detectors AiD Project (AiD project: 
Development of dedicated systems based on accelerators and 
detectors of ionizing radiation for medical therapy and indetection of 
hazardous materials and toxic wastes) in The Polish National Centre 
for Nuclear Research. 
Materials and Methods: The pre-prototype of the control system 
works with the registration and verification software developed in the 
National Centre for Nuclear Research and Treatment Planning System 
PHJ Prague.The system analysis was performed to assess the security 
operation responsible for the dose off including verifications of error 
messages of measurement doses related to dosimetry measurement 
devices, mechanical failure of accelerator elements and use by an 
unauthorized user. Before starting the irradiations various cases 
ofoperator errors, omissions in remote data retrieval therapy and 
manual dialing parameters were tested. During the irradiations 
different schedules of dose measurements device and accelerator 
mechanical device errors were tested. 
Results: Safety of the patient during the irradiation is dependent on 
the manufacturer of the treatment devices. The accelerator control 
system was designed to meet all treatment parameters obtained from 
the Treatment Planning System and terminated irradiation if the 
parameters were inconsistent with the plan. The pre-prototype of the 
control system met all requirements. 
Conclusions: The analysis of the cases used in this study showed that 
the control system created as a pre-prototype can be the first step to 
create clinically acceptable software. 
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Purpose/Objective: The importance in local control and toxicity of 
optimal applicator placement in cervical cancer brachytherapy (BT) is 
well established. Nevertheless uterine perforation remains a frequent 
complication, generally undetected by classic QA measures of 2D BT 
to assess the adequacy of implant placement. 3D BT based on CT 
imaging allows optimal visualization of applicator’s position in respect 
to the OARs thus enabling the possibility of dose optimization. Aim of 
this work is to define the dosimetric impact on OARs of undetected 
uterine perforation when a standard point A optimized dose 
distribution is applied and the eventual dosimetric gain achievable 
with 3D CT-based dose optimization. 
Materials and Methods: 23 CT-based tandem/ovoids BT applications 
complicated by uterine perforation were selected. All patients had a 
FIGO IIB cervical cancer and were planned to receive radio-
chemotherapy (1.8 Gy per fraction up to 45 Gy with concomitant 
weekly cisplatin) and BT (4 fractions of 7 Gy) with a plan optimized to 
HRCTV drawn according clinical findings at the time of BT. The 
planning aim for dose optimization was to keep the D2cc value for 
rectum, bladder and sigmoid below 4.6 Gy, 6.5 Gy and 4.6 Gy 
respectively. Moreover a standard point A plan was calculated and 
respective DVH parameters for HRCTVs and OARs compared. Wilcoxon 
test was applied for statistical data analysis and calculated with 
Matlab 7.11 software (Mathworks Inc). 
Results: Median HRCTV width was 46 mm (37-64 range). Median 
HRCTV D90 and OAR D2cc values achieved with standard or the 
optimized plan are listed in table 1. When the standard plan was 
applied the intended dosimetric constraint for rectum, bladder and 
sigmoid were not achieved in 15 (60%), 10 (43,5%) and 19 (82%) 
applications respectively while they were always met in the 3D 
optimized plans. In 8 out of the 19 standard plans where the 
dosimetric constraint was exceeded the sigmoid D2cc was higher than 
8Gy. In 3 cases out of 19 it was higher than10Gy. 
 
*p-value < 0,001 Standard plan Optimized plan 
HRCTV D90 (Gy) * 7,5 (range 6 – 10,1) 6,4 (range 4,8 – 9,6) 
Rectum D2cc (Gy) * 5,2 (range 2,33 - 6,73) 4,5 (range 2,68 – 4,71) 
Bladder D2cc (Gy) 6,3 (range 3,8 - 17,6) 6,1 (range 4,34 – 6,4) 
Sigmoid D2cc (Gy)* 6,8 (range 1,78 – 16,75) 2,9 (range 0,8 – 4,65) 
 
Conclusions: The occurrence of uterine perforation should be kept as 
low as possible by the routine use of US during GYN BT implantation. 
When uterine perforation occurs it is easily detected on CT images but 
rarely on the orthogonal films. In case of uterine perforation 2D 
planning may thus results in potentially dangerous over dosage of 
OARs. 3D optimization allows keeping OAR dose within tolerance 
constraints just minimally compromising HRCTV D90 coverage.  
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Purpose/Objective: To evaluate if glycosaminoglycan’s (GAG) 
administration as hyaluronicacid (HA) intravesical instillations reduces 
the rate of acute and lateradio induced bladder toxicity as a 
complication of radiation treatment in gynecological cancer. A review 
of the literature was done to analyse which treatments were used in 
this field and the HA role among them. 
Materials and Methods: Retrospective study of 70 patients diagnosed 
with cervical and endometrial cancer treated between May 2010 and 
June 2012 with high-dose rate brachytherapy (HDR-BT) with or 
without external beam radiotherapy (EBRT). 50/70 received an EBRT 
total dose of 45-50.4 Gy delivered in 25-28 fractions followed by 
brachytherapy (HDR-BT) 11Gy in 2 fractions. The remaining 20 
patients received HDR-BT alone, 21 Gy in 3 fractions. All of them 
received intravesical instillations of hyaluronic acid (HA) immediately 
after each HDR-BT fraction according to recommendations of medical 
prospectus. 5/50 (10%) presented G1-2 toxicity before brachytherapy. 
RTOG/EORTC scale was used to evaluate acute and late toxicity rates 
at 3, 6, 12 and 18 months after HDR-BT. A review of the literature was 
made using Medline research with the following criteria: HA 
prevention and gynecological cancer and radioinduced cystitis. 
Results: Regarding our study, no upgrading toxicity was observed in 
patients treated with combined HDR-BT and EBRT (50/70) during the 
follow-up period. None of the patients (20/70) treated with exclusive 
HDR-BT had bladder toxicity neither acute nor chronic. No adverse 
events related to HA were observed. After reviewing literature, we 
observed that HA instillations have demonstrated effectiveness in 
relieving symptoms associated with interstitial cystitis, considering a 
similar biological pattern to radioinduced cystitis. 2 studies with these 
characteristics and written by the same authors were found: P. 
Samper et al. The first one is an abstract presented at ASCO 2003 with 
90 patients and the other a retrospective study with 95 patients; both 
of them demonstrate that HA instillations are effective in 
radioinduced cystitis prevention.  
Conclusions: Intravesical instillations of hyaluronic acid are effective 
in preventing radiation cystitis. It is safe and well tolerated. Given the 
scarcity reports on this subject, it is difficult to draw any firm 
conclusions about standard recommendations. However, based on our 
experience, intravesical HA can be used as routine before each 
brachytherapy fraction in gynecological cancer. A prospective 
randomized control study with a large number of patients and long 
term follow-up is recommended. 
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Vaginal brachytherapy for endometrial cancer: pulsed dose rate 
versus low dose rate, a single institution analysis. 
